SCHEMBL15051665

SCHEMBL15051665

O=Cc1cn(-c2ccnc(Cl)c2)nc1-c1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.46
ALDH1A1 P00352 7/20 0.45
KMT2A Q03164 6/20 0.45
SMN1; SMN2 Q16637 6/20 0.45
KDM4E B2RXH2 5/20 0.43
HPGD P15428 3/20 0.43
POLB P06746 3/20 0.41
PSMD14 O00487 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
ESR1 P03372 1/20 0.40
MEN1 O00255 5/20 0.39
RAB9A P51151 2/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051894 0.80 ALDH1A1 (0.47) ALDH1A1KMT2ASMN1; SMN2KDM4EHPGD
SCHEMBL15051624 0.79 KDM4E (0.45) ALDH1A1KDM4EPKM
SCHEMBL15051508 0.79 SCN9A (0.37) ALDH1A1KMT2ASMN1; SMN2KDM4EHPGD
SCHEMBL15050751 0.76 KCNA5 (0.34) ALDH1A1KMT2ASMN1; SMN2KDM4EGLA
SCHEMBL15051559 0.76 AKT1 (0.36) ALDH1A1KMT2ASMN1; SMN2KDM4EGLA
SCHEMBL15051300 0.76 MAPT (0.51) ALDH1A1KMT2AKDM4EHPGDPOLB
SCHEMBL2558778 0.76 PTGS2 (0.52) PTGS2ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL15051049 0.75 KDM4E (0.36) ALDH1A1KMT2ASMN1; SMN2KDM4EHPGD
SCHEMBL15051533 0.75 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2KDM4EHPGD
SCHEMBL15050926 0.73 EGLN1 (0.39) KMT2APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 PTGS2 1804/4885ALDH1A1 2884/4885KMT2A 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.